Linagliptin Sandoz (Linagliptin)

Linagliptin works by selectively inhibiting the dipeptidyl peptidase‑4 (DPP‑4) enzyme. This inhibition raises endogenous levels of the incretin hormones GLP‑1 and GIP, which stimulate insulin secretion and suppress glucagon release in a glucose‑dependent manner, thereby lowering both fasting and post‑prandial blood glucose.

The specific dose of Linagliptin Sandoz is determined by the prescribing healthcare professional based on the individual patient's clinical condition, renal function, and concomitant therapies. Patients should follow the prescriber’s instructions and not adjust the dose without medical guidance.

Safety of linagliptin in pregnancy and lactation has not been established. It should be avoided unless the potential benefit to the mother outweighs any possible risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternative treatment options with their healthcare provider.

To place an order, submit an enquiry on the Linagliptin Sandoz product page at gnhindia.com, indicating the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Linagliptin shares the same class mechanism as other DPP‑4 inhibitors but is unique because it is eliminated primarily via the entero‑hepatic route, allowing use without dose adjustment in patients with renal impairment. Efficacy and safety profiles are generally comparable, though individual tolerability and drug‑interaction potential may differ among agents.

Linagliptin Sandoz tablets should be stored at room temperature, below 25 °C, in the original blister pack or container. Protect the product from moisture, excessive heat and direct sunlight. Keep out of reach of children and do not use after the expiry date printed on the packaging.

Linagliptin Sandoz is taken orally, usually once daily, with or without food. The tablet should be swallowed whole with a glass of water. Patients should follow the dosing schedule prescribed by their clinician and maintain consistent timing each day to ensure stable drug levels.

Serious adverse events, although rare, include pancreatitis (characterized by severe abdominal pain), severe hypersensitivity reactions such as anaphylaxis, and serious skin reactions like Stevens‑Johnson syndrome. Patients should seek immediate medical attention if they experience persistent abdominal pain, rash, swelling, or any signs of an allergic reaction.

Linagliptin should be avoided in individuals with a known hypersensitivity to linagliptin or any component of the formulation. Caution is also advised for patients with a history of pancreatitis, severe hepatic impairment, or uncontrolled heart failure, and it is contraindicated during pregnancy and lactation unless clearly justified by a physician.